Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

Study Population

IS Ide Smets
TP Teresa Prezzemolo
MI Maya Imbrechts
KM Klara Mallants
TM Tania Mitera
SH Stéphanie Humblet-Baron
BD Bénédicte Dubois
PM Patrick Matthys
AL Adrian Liston
AG An Goris
request Request a Protocol
ask Ask a question
Favorite

A study population of 112 unrelated patients of Caucasian descent fulfilling McDonald 2010 criteria for MS was included between May and November 2017 at the University Hospitals Leuven. We specifically selected untreated patients and patients treated with IFN-β or fingolimod. Overlap with our earlier work (1) is 14% (6/41 untreated), 21% (9/42 IFN-β) and 34% (10/29 fingolimod), respectively, where overlapping patients were sampled at an earlier time-point. The same treating physician (B.D.) collected clinical and demographic data during patient follow-up ( Table 1 ). The study was approved by the Ethics committee of the University Hospitals Leuven (S60222).

Study population.

(SD, Standard deviation; BO, bout onset; PP, primary progressive; MSSS, multiple sclerosis severity score).

Copyright and License information:  ©2021 Smets, Prezzemolo, Imbrechts, Mallants, Mitera, Humblet-Baron, Dubois, Matthys, Liston and Goris
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A